Bellevue Group’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-7,711
| Closed | -$227K | – | 180 |
|
|
2025
Q4 | $227K | Sell |
7,711
-1,630
| -17% | -$44.3K | ﹤0.01% | 151 |
|
|
2025
Q3 | $241K | Sell |
9,341
-1,229,327
| -99% | -$34.3M | 0.01% | 131 |
|
|
2025
Q2 | $34.2M | Sell |
1,238,668
-279,454
| -18% | -$7.36M | 0.75% | 34 |
|
|
2025
Q1 | $43M | Sell |
1,518,122
-82,755
| -5% | -$2.94M | 0.96% | 25 |
|
|
2024
Q4 | $66.6M | Buy |
1,600,877
+41
| +0% | +$1.96K | 1.28% | 23 |
|
|
2024
Q3 | $107M | Buy |
1,600,836
+37,101
| +2% | +$3.41M | 1.73% | 15 |
|
|
2024
Q2 | $186M | Sell |
1,563,735
-147,354
| -9% | -$18.6M | 3.02% | 10 |
|
|
2024
Q1 | $182M | Sell |
1,711,089
-197,331
| -10% | -$19.9M | 2.78% | 8 |
|
|
2023
Q4 | $190M | Buy |
1,908,420
+413,095
| +28% | +$34.7M | 2.9% | 7 |
|
|
2023
Q3 | $154M | Sell |
1,495,325
-29,734
| -2% | -$3.32M | 2.49% | 8 |
|
|
2023
Q2 | $185M | Sell |
1,525,059
-26,647
| -2% | -$3.55M | 2.64% | 7 |
|
|
2023
Q1 | $238M | Sell |
1,551,706
-30,622
| -2% | -$5.05M | 3.46% | 6 |
|
|
2022
Q4 | $284M | Buy |
1,582,328
+22,527
| +1% | +$3.68M | 3.77% | 5 |
|
|
2022
Q3 | $184M | Sell |
1,559,801
-17,550
| -1% | -$2.66M | 2.65% | 6 |
|
|
2022
Q2 | $225M | Sell |
1,577,351
-61,998
| -4% | -$8.86M | 3.19% | 5 |
|
|
2022
Q1 | $282M | Sell |
1,639,349
-69,900
| -4% | -$11.8M | 3.28% | 5 |
|
|
2021
Q4 | $434M | Sell |
1,709,249
-18,100
| -1% | -$5.29M | 4.47% | 1 |
|
|
2021
Q3 | $665M | Sell |
1,727,349
-814,951
| -32% | -$301M | 6.75% | 1 |
|
|
2021
Q2 | $597M | Sell |
2,542,300
-267,650
| -10% | -$47.8M | 5.83% | 1 |
|
|
2021
Q1 | $368M | Sell |
2,809,950
-136,963
| -5% | -$19.8M | 3.89% | 2 |
|
|
2020
Q4 | $308M | Sell |
2,946,913
-395,037
| -12% | -$40M | 3.53% | 3 |
|
|
2020
Q3 | $236M | Sell |
3,341,950
-3,000
| -0.1% | -$209K | 3.27% | 6 |
|
|
2020
Q2 | $215M | Sell |
3,344,950
-605,231
| -15% | -$33.1M | 3.04% | 9 |
|
|
2020
Q1 | $118M | Sell |
3,950,181
-984,900
| -20% | -$22.7M | 2.29% | 11 |
|
|
2019
Q4 | $96.5M | Buy |
4,935,081
+91,000
| +2% | +$1.61M | 1.53% | 16 |
|
|
2019
Q3 | $77.1M | Buy |
4,844,081
+119,835
| +3% | +$1.77M | 1.43% | 19 |
|
|
2019
Q2 | $69.2M | Buy |
+4,724,246
| New | +$101M | 1.18% | 27 |
|
Other funds holding MRNA
Bellevue Group's MRNA Position: Q1 2026 in Review
Bellevue Group sold out of Moderna (MRNA) in Q1 2026, closing a stake of 7,711 shares — an estimated $227K sold.
Bellevue Group first reported a position in MRNA in Q2 2019 and held it in 27 quarters. The position peaked at $665M in Q3 2021. 728 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.
- Bellevue Group reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
- Bellevue Group sold 7,711 Moderna shares in Q1 2026, an estimated $227K.
- Bellevue Group first reported a position in Moderna in Q2 2019 and held it in 27 quarters.
- Bellevue Group's Moderna position peaked at $665M in Q3 2021.
- 728 funds tracked by Wall St. Rank held Moderna as of Q1 2026.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.